GlassScriptPhysician profile
Blake P Sampson
NPI 1588007520
$1,566.82
in general payments reported to CMS, 2019-2025
18 companies · $429 in 2025
The $429 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.91 · 2022: $260 · 2023: $308 · 2024: $556 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $422.89 | 2022-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $214.64 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $197.04 | 2024-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $166.08 | 2022-2024 | Sotyktu |
| Amgen INC. | $122.99 | 2021-2024 | Otezla |
| Ucb, INC. | $115.29 | 2024-2025 | Bimzelx |
| Biowound Solutions, INC. | $43.73 | 2025 | Bio-Connekt |
| Janssen Biotech, INC. | $37.22 | 2023-2025 | Tremfya |
| Integra Lifesciences Corporation | $35.95 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Mimedx Group, INC. | $35.36 | 2024-2025 | |
| Incyte Corporation | $29.73 | 2022-2023 | Opzelura |
| Leo Pharma INC. | $25.86 | 2025 | Adbry |
| Kyowa Kirin, INC. | $24.31 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.07 | 2025 | Spevigo |
| Genzyme Corporation | $20.86 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $19.30 | 2025 | Ayvakit |
| Arcutis Biotherapeutics, INC. | $19.17 | 2024 | Zoryve |
| Biofrontera INC. | $15.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Sampson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.